The effect of co-expression costimulatory molecule CD80 on uptake of antigen peptide-MHC class I-GFP complex by specific T cells

XIA LIU*, LEILEI ZHANG*, XINGQIAN ZHANG, HAI YU, XIAOPING ZHAO, JIAN LU, GUANXIANG QIAN and SHENGFANG GE

Research Center for Human Gene Therapy, Department of Biochemistry and Molecular Biology, School of Medicine, Shanghai Jiao Tong University, Shanghai, P.R. China

Received January 2, 2007; Accepted February 22, 2007

Abstract. CD80, a costimulatory molecule, plays an important role in eliciting antitumor immunity. Without costimulation, recognition of antigens by T cells may not cause a response, even if tumor cells express MHC class I molecules and specific antigens. On the basis of the recombinant GFP-tagged Kb molecule, we constructed a co-expression vector of CD80 and GFP-tagged Kβ molecules. The recombinant fusion was transfected into mouse melanoma B16 cells by electroporation; positive cells were obtained by G418 screening. Highly expressing monoclonal cells, irradiated by 137Cs, were used to immunize mice to obtain specific T cells, which were then cultivated with tumor cells in vitro and examined with a laser confocal microscope. The evident and intense uptake of the antigen peptide-MHC class I-GFP complex by specific T cells was visualized from the culture of B16/CD80-Kβ-GFP and T cells. However, little uptake was observed from the culture of B16/Kβ-GFP and T cells. These results show that co-expression of CD80 molecules with Kβ, an MHC class I molecule, on the surface of B16 tumor cells can enhance the response of specific T cells and thus increase the uptake of the antigen peptide-MHC class I-GFP complex. The absorbed green fluorescence was concentrated mainly on the T cell surface, and this result might pave the way to eluting specific antigen peptides directly from T cells to find and isolate novel tumor-specific antigen peptides.

Introduction

T cell-mediated cellular immunity is the main source of antitumor activity. The signal following detection of antigen-major histocompatibility complexes (MHCs) by the antigen receptor is not sufficient to elicit an immune response. Optimal activation of T cells requires two distinct signals. The first signal is mediated by MHC-restricted, antigen-specific triggering of the T-cell receptor (TCR) complex. The second signal comes from an antigen-independent mechanism, and is termed costimulation. The second signal is delivered by costimulatory molecules on the antigen-presenting cells (APCs) through their counter-receptors on the T lymphocytes. Without costimulation, exposure of T cells to an antigen may not cause a response (1-3).

There are several molecules that can provide costimulation. Particular interest has been given recently to B7 (B7.1 or B7.2), which is the natural ligand for the CD28 and cytotoxic T lymphocyte (CTLA-4) counter receptors on T cells, and it is one of the most pivotal costimulatory molecules for inducing functional T-cell responses. CD80 is constitutively expressed on T cells; CTLA-4 is induced and expressed only on activated T cells. When CD28 binds CD80, T cells are stimulated to differentiate and proliferate. CTLA-4 has a higher affinity for CD80 and appears to deliver a negative signal to T cells. Stimulation of T cells in the absence of CD80 (B7.1) or B7.2-mediated costimulation results in impaired proliferation, reduced production of cytokine, and altered Th1/Th2 balance (4). The CD80 (B7.1) molecule was first identified as a member of the B7 family, and is expressed mostly on dendritic cells, activated macrophages, and activated B cells. It plays an important role in the activation of T cells, because data show that tumor cells can induce antigen-specific tolerance and make the tumor cell immune anergy on the basis of MHC class I-restricted antigen presentation with lack of expression of costimulatory ligands. Other investigators have shown that tumor cells genetically engineered to express...
CD80 induce CD8+ cytotoxic T cells that provide protective immunity by lysing CD80 tumor cells (5-7).

Tumor cells seldom express CD80 molecules, except for those derived from B cells. One of the important mechanisms by which tumor cells escape immunity killing is that they do not, or only weakly, express CD80 molecules (8). The application of molecular biology techniques to transfect costimulatory molecules into tumor cells can lead to the strengthening of the effects of T cells, including cell proliferation, secretion of cytokine and CTL activity (9-11).

Little uptake was observed from the culture of B16/Kb-green fluorescent protein (GFP) and T cells when the recombinant GFP-tagged Kb molecule was transfected into the mouse melanoma B16 cells lacking the expression of MHC class I molecules (12,13). Thus, we constructed a co-expression vector containing CD80 and GFP-tagged Kb molecules to enhance the expression of the costimulatory CD80 molecule and provide a foundation for the further activation of the antigen-specific T cells and induction of the effective anti-tumor immunity by enhancing the tumor cellular immunity responses through the synergetic effect of MHC class I molecules and costimulatory molecule.

Materials and methods

Experimental animals, cell lines and plasmids. Female C57BL/6 mice, 6-8 weeks old, were treated according to the NIH Guidelines for Animal Care in the Experimental Animal Center of Shanghai Jiao Tong University School of Medicine. Mouse melanoma B16 cells were obtained from ATCC, maintained in RPMI-1640 medium supplemented with 10% bovine calf serum and cultured at 37˚C in a 5% CO2 incubator. Escherichia coli strain JM109 was bought from ATCC, eukaryotic expression vector pGL3/CD80, and pcDNA3.0/mKb-GFP were constructed and conserved by our laboratory.

Reagents. The following materials were obtained: RPMI-1640 medium and G418 (Invitrogen), bovine calf serum (PAA Laboratory GmbH Co.), plasmid purification kit MIDIPREP (Gibco), fetal calf serum (HyClone), TRizol® total RNA purification kit and reverse transcription reaction agent (Invitrogen), polymerase chain reaction (PCR) agent and restriction endonuclease (Takara), fluorescein isothiocyanate (FITC)-anti-mouse CD80 antibody, anti-mouse H-2Kb antibody and PE-anti-mouse TCR-ß monoclonal antibody (eBioScience), mononuclear cells isolation solution (1.077 g/ml) was added.

Construction of the co-expression vector of pGL3/CD80-mKb-GFP. Vectors pcDNA3.0/mKb-GFP and pGL3/CD80 were digested with BglII and Smal individually, and then mKb-GFP was inserted into pGL3/CD80 to obtain the co-expression vector pGL3/CD80-mKb-GFP.

mKb-GFP was driven by the cytomegalovirus (CMV) promoter and CD80 was driven by the SV40 promoter (plasmid maps, Fig. 1). The preparation of plasmid following the instructions supplied with the plasmid purification kit (Gibco).

Electroporation transfection of melanoma B16 cells. B16 cells were transfected into pGL3/CD80-mKb-GFP and pcDNA3.0/mKb-GFP, which were digested with BglII, at 280 mV, 960 μF (14). pGL3/CD80-mKb-GFP was transfected with 1/50 of plasmid pSV40/neo. After electroporation transfection for 48 h, RPMI-1640 medium containing G418 (0.5 mg/ml) was added and the medium was changed until recombinant cells were produced in good condition. Normally, some clones were seen after screening for a week, and a stable transfection cell line was constructed after 3 weeks, then the monoclonal cell line was cultured by limiting dilution techniques.

Reverse transcription (RT)-PCR. For the reverse transcription system (20 μl), 5 μg of total RNA, 2 μl of random primer, and 1 μl of 10 mM dNTP were added to 6 μl of diethyl pyrocarbonate-treated water. After mixing, they were denatured at 65˚C for 5 min followed by immediate immersion in an ice-water bath. Then 4 μl of 5X reaction buffer, 2 μl of 0.1 M DTT, and 1 μl of RNaseOUT were added and mixed at 37˚C for 2 min. Finally, M-MLV reverse transcriptase was added, and mixed at 25˚C for 10 min, then at 70˚C for 15 min.

Amplification of target genes. For CD80, the upstream primer was 5’-TCC CAA GCT TCA AAG CAT CTG CT-3’, and the downstream primer was 5’-TGC TCT AGA CTA AAG GAC GCT GGT C-3’; for GFP, the upstream primer was 5’-TAG AAT TCA TGG TGA GCA AGG CGA GGA GCT G-3’, and the downstream primer was 5’-GAT CTA GAG TCG CGG CCG CCT TTG TAC AG-3’.

For the PCR reaction system (50 μl), 10X reaction buffer, 1 μl of 10 mM dNTP, 2 μl of RT reaction product, and 39.5 μl of double-distilled water were used. The mixture was denatured by heating at 94˚C for 5 min followed by immediate immersion in an ice-water bath, then 0.5 μl of Taq DNA polymerase (5 U/μl) was added.
The PCR cycle was as follows: GFP, 94°C for 40 sec, 58°C for 1 min, 72°C for 1 min; CD80, 94°C for 1 min, 60°C for 1 min, 72°C for 1 min; repeated 30 times, and then extended at 72°C for another 10 min.

After the reaction, 5 μl of PCR product was extracted and run on 1.2% (w/v) agarose gel at 3 V/cm. The gel was scanned under a UV lamp, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control.

**Flow cytometry.** The detection of GFP in fusion protein was as follows: 1x10⁶ target cells were collected per sample, washed twice with PBS, centrifuged at 1000 rpm for 5 min, and then suspended in 200 μl of PBS. The sample of B16 cells was used as a GFP-negative control.

The detection of CD80 was as follows: 1x10⁶ target cells were collected per sample, washed with cleaning solution [PBS containing 0.1% (w/v) sodium azide and 0.1% (w/v) bovine serum albumin], and centrifuged at 1000 rpm for 5 min. Then 100 μl of FITC-anti-mouse CD80 antibody (diluted 1/100) was added and the mixture was cooled in an ice-water bath in the dark for 30 min, washed twice with cleaning solution and then 200 μl of PBS fixative containing 2.5% (v/v) formaldehyde was added.

The detection of CD8⁺ T cells was as follows: the isolated mononuclear cells (5x10⁵ cells) were taken from the spleens of immunized mice, washed twice with cleaning solution and resuspended in 100 μl of cleaning solution. Then 1 μl of FITC-anti-mouse CD8 antibody was added and the sample was kept on ice for 30 min, before being washed twice with cleaning solution and resuspended in 200 μl of PBS fixative containing 1% (v/v) fetal calf serum and 2.5% (v/v) formaldehyde.

**Immunization of mice with gene-modified B16 cells.** Female C57BL/6 mice, 6-8 week old, were divided into three groups of five mice: group 1, hypodermic injection of monoclonal B16/CD80-K⁺-GFP cells (1x10⁶ cells/per mouse) irradiated with 1³⁷Cs; group 2, hypodermic injection of monoclonal B16/K⁺-GFP cells (1x10⁶ cells/per mouse) irradiated with ¹³⁷Cs; group 3, hypodermic injection of monoclonal B16 cells (1x10⁶ cells/per mouse) irradiated with ¹³⁷Cs. Mice were immunized by hypodermic injection and again after 1 week (15).

**Preparation of mononuclear cells and isolation of T cells.** C57BL/6 mice were sacrificed 14 days after the last immunization, the spleens were removed and ground into a cell suspension, which was added to 3 ml of mononuclear cell separation liquid and centrifuged at 1500 rpm for 20 min at 20°C. Interface cells were removed, washed twice with PBS, placed into a 6-well plate and cultured with RPMI-1640 medium containing 10% bovine calf serum. Recombinant human IL-2 was added to a final concentration of 500 IU/ml to support the growth of lymphocytes. Mononuclear cells were incubated at 37°C, in a 5% CO₂ atmosphere, for 48 h, and then T cells were isolated and enriched according to the instructions supplied with the T cell isolation kit. Before culturing the tumor cells with specific T cells, the T cells were cultured in the medium without IL-2 for 48 h to keep them synchronized.
of the monoclonal cell line B16/CD80-Kb-GFP were expressed stably.

**FACS analysis of monoclonal cell lines.** The expression of the GFP fusion protein of K\(^b\)-11B and K\(^b\)-9C was 11.59 and 4.93%, respectively, as determined by flow cytometry (Fig. 3A). However, the expression of CD80 in cell lines CD80-10F and CD80-10H was 36.44 and 34.15%, respectively (Fig. 3B). On the basis of the above results, we chose the high-expression monoclonal cell lines K\(^b\)-11B and CD80-10F for the following experiment. In addition, to further describe the expression of each transfected gene of the monoclonal cell lines we used, we measured the expression of K\(^b\) molecules of the fusion protein using FITC-anti-mouse H-2K\(^b\) antibody. The results showed that the expression of K\(^b\) in cell lines K\(^b\)-11B and CD80-10F was 62.93 and 47.30%, respectively. The co-expression of CD80 in cell line CD80-10F was measured as 40.73% using the FITC-CD80 antibody (Fig. 4).

**FACS analysis of CD8\(^+\) T cells of mononuclear cells.** To compare the antigen-specific CD8\(^+\) T cells in the body when mice were immunized with each tumor cell irradiated with isotope, we chose the mononuclear cell that had the most CD8\(^+\) T cells according to the number of CD8\(^+\) T cells of five mice of each group. Finally, we chose the B16/CD80-Kb-GFP mononuclear cell (16.10%), the B16/Kb-GFP mononuclear cell (16.74%) and the B16 mononuclear cell (18.33%), and isolated their T cells for use in the following experiments (Fig. 5).

**Observation of the uptake of the antigen peptide-MHC class I-GFP complex by T cells using laser scanning confocal fluorescence microscopy.** The state of gene-modified B16 cells and specific T cells after they were cultured together for 1 h was observed using a laser scanning confocal fluorescence microscope. Fig. 6A shows that little uptake of the antigen peptide-MHC class I-GFP complex by specific T cells was observed from the culturing of B16/Kb-GFP with T cells. However, the evident and intense uptake of the antigen peptide-MHC class I-GFP complex by specific T cells was visualized from the culturing of B16/CD80-Kb-GFP with T cells. Moreover, the absorbed green fluorescence was concentrated mainly on the T cell surface (Fig. 6B and C). In a previous version of Fig. 6C, a number of T cells having taken up the GFP green fluorescent complex were observed. In order to prove that the green fluorescent points are T cells and not some other components, the cell indicated by the red arrow was further amplified, indicating the integrity of its cell structure. These results show that the co-expression of costimulatory molecule CD80 with K\(^b\), an MHC class I molecule, on the surface of tumor cells can enhance the reaction between T cells and tumor cells, and increase the uptake of the antigen peptide-MHC class I-GFP complex.

**Dual-channel fluorescence analysis of the uptake of the antigen peptide-MHC class I-GFP complex by T cells.** T cells were tagged with PE-anti-mouse TCR antibody to prove the uptake of the antigen peptide-MHC class I-GFP complex by T cells. Since GFP and phycoerythrin (PE) use the same excitation wavelength, dual channel technology can be used to observe the green fluorescence of GFP and the red fluorescence of PE. Fig. 6 shows that T cells exhibited only the red fluorescence of PE when B16 cells were cultured with specific T cells (Fig. 7A). However, when B16/Kb-GFP cells were cultured
with specific T cells, the T cells exhibited both the green fluorescence of GFP and the red fluorescence of PE (Fig. 7B). These results confirmed the uptake of the GFP complex by T cells on the tumor cell surface, and the phenomenon is more obvious when T cells were cultured with B16/CD80-Kb-GFP cells (Fig. 7C and D). These figures show clearly that T cells take up the GFP green fluorescent complex. It is interesting to observe the phenomenon of immune synapses formed by the interaction of the tumor cells with specific T cells, as shown in Fig. 7D. Thus, these results showed that the expression of costimulatory molecule CD80 with Kb, an MHC class I molecule, on the surface of tumor cells can enhance the reaction between T cells and tumor cells, and increase the uptake of the antigen peptide-MHC class I-GFP complex.

Discussion

T cell-mediated cellular immunity is the main anti-tumor resource of the organism. Optimal T-cell activation requires two distinct signals. Recently, the cytokine IL-12 has received much attention in the activation of T cells and exciting the immunity response of the organism, and has even been considered to be a third signal. IL-12 is a potent inducer of interferon production by natural killer cells and T-helper lymphocytes. It plays a crucial role in the early induction of immune responses by triggering the differentiation of T-helper lymphocytes towards the Th1 subtype (16).

When IL-12 is offered alone to stimulate the tumor cell HepG2, the killing effect of CTL is not obviously strengthened, although it is when co-transfected with CD80. This indicates that the microenvironment of cytokines is an important link to determine the differentiation of T cells and the subsequent characteristics of the immune response (17). Some studies showed that the expression of CD80 contributes to the activation of T cells, but it does not cause the production of Th1 cells, suggesting that it may be some factor produced by the tumor cells that suppresses the production of Th1.

That is to say, we can co-transfect CD80 and some cytokines to stabilize the cooperation of the microenvironment of T cells in the antitumor immunity responses.

The search for a tumor antigen peptide has become a focus of the present tumor research field. The tumor antigen peptide is presented to the cell surface and recognized by the corresponding T cell receptor after combining with the MHC molecule, thus activating the cytotoxicity of the T lymphocyte, making the organism produce a specific anti-tumor immunity response. Therefore, they have the potential for wide application in fields such as tumor immunity inoculation and immunization therapy. Because there are few known tumor antigen peptides, and we have not found clear tumor antigens to most clinical tumors, the search for tumor antigen peptides has become urgent.

Several methods have been used to identify antigen CTL epitopes (18-20). If the amino acid sequence of a protein antigen is known, overlapping peptides of 8-10 amino acid residues can be synthesized as the target. This method has been used to identify a number of CTL epitopes of virus proteins; CTL epitopes can be found by searching the binding sequence of MHC and determining the affinity of the potential antigen peptide with the MHC molecule; the majority of
human tumor antigens now known have been identified by the transfection of genomic DNA or cDNA libraries into cells expressing the appropriate MHC molecule, followed by the identification of transfectants using cytokine release or lysis by human T cells with specific anti-tumor reactivity. These methods are selected directly from the perspective of finding antigenic peptides, the drawback is their poor specificity and large workload, just like looking for a needle in a haystack.

With elucidation of the recognition mechanism of T cells, the study of the recognition of T cells for tumor antigen has increased (21-25). A specific CTL clone can be induced in vitro using a tumor antigen peptide; it has become a powerful tool for finding and identifying tumor antigen peptides, and could be called a specific cell probe. Therefore, the reverse immunology technique has been used to identify candidate proteins. Using in vitro sensitization techniques, T cells against candidate antigens have been generated successfully. If these specific T cells can also recognize the intact tumor cells, such proteins are considered to be tumor antigen proteins. Therefore, peptides eluted selectively from the surface of tumor cells were exposed to the antigen-presenting cells to test the responses of the anti-tumor lymphocyte, and many tumor antigens recognized by CD8+ cells have been confirmed in this way (26).

Through the recognition and uptake of specific T cells in vitro, we used weak acid elution (27,28) to acquire specific tumor antigen peptides based more directly on the phenomenon of TCR-mediated-endocytosis (29), using tumor antigen processing and presentation by MHC class I molecules. Because MHC class I molecules are expressed by tumor cells at a much lower level than the professional antigen-presenting cells, the proliferation of T lymphocyte cytotoxicity could not occur during the effector phase of the anti-tumor immune response, and the tumor escapes from the immune response. Recent studies have shown that many costimulatory molecules, in addition to their essential role in the development of the antigen-specific humoral response, appear to facilitate T-cell activation in response to low-affinity or low-abundance antigens by lowering the threshold required for activation and
promoting the survival of activated T cells when the antigen concentration is not high, which helps to produce anti-tumor effector cells more effectively (30,31). Therefore, co-expression of the tumor cell costimulatory molecule CD80 was used to observe whether it can enhance the response of T cells, overcome the immune escape of the tumor cells that increases the uptake of the tumor cell surface antigen peptide-MHC class I molecule-GFP complex and provide an experimental basis for the further isolation and identification of tumor-associated antigen peptides.

Approaches to increase the expression and function of the transgene are under study, including the possible use of lentiviral vectors, the use of more powerful promoters specific to T cells, the use of higher affinity TCRs that can mediate CD8-independent anti-tumor reactivity in CD4 cells, the further optimization of T cell transduction methods, and the production of higher titer good manufacturing practice-quality viruses. In this study, we constructed the co-expression vector of CD80 and GFP-tagged K\(^+\) molecules to enhance the expression of costimulatory molecule CD80 and further provide the second stimulus signal needed for the activation of T cells to induce the effective anti-tumor immunity response. By using the recombinant GFP-tagged K\(^+\) molecule, we observed TCR-mediated endocytosis of the antigen peptide-MHC class I complex through transfer of GFP protein between cells. The results show that little uptake of the antigen peptide-MHC class I-GFP complex was observed from the co-culturing of the results reported by Huang (29), who showed that L\(^+\)-GFP molecule on the target cell surface can be almost the entire cell membrane, and these are different from the results reported by Huang et al (29), who showed that L\(^+\)-GFP molecule on the target cell surface can be internalized by T cells when T cells recognize the complex for only 30 min and the green fluorescent area was found in T cells. An explanation for this difference may be the fact that in our research T cells were immunized in vivo and separated, and their recognition response to tumor cells was stronger than the response of 2C T cells plus peptide QL9 to the target cells. Because, in our study, specific T cells may take up almost all of the antigen peptide complex presented by the MHC class I molecule, including known and unknown antigen peptide, and specific T cells might not be able to ingest all of these at once. This seems to provide a new opportunity for us to elute specific antigen peptides from T cells directly, and would pave the way for further studies with the aim of finding new methods to discover and test novel tumor-specific antigen peptides.

Acknowledgements

This study was supported by the National Key Program for Basic Research of China (2004CB518804) and the Science and Technology Commission of Shanghai (04JC14041).

References
